Harbingers of Things to Come in Gene Therapy
By Josh P. Roberts,
Genetic Engineering & Biotechnology News
| 04. 02. 2021
Photo by CDC on Unsplash
It is one thing to anticipate what gene therapy will look like in 5 years, let alone 10. The deeper we peer into the crystal ball, the less we can rely on what we see. So, let us put scrying and intuition aside. Instead, let us take a close look at gene therapy’s present state and how it has come to be. We will identify the forces behind gene therapy’s recent advances—as well as newly emergent forces—and we will keep in mind that these forces will likely wax and wane. Then we will be better able to predict what gene therapy will look like in the near future (or even the not-so-near future).
Vector improvements
Gene therapy can be divided into in vivo and ex vivo treatments. In the former, genetic material is delivered directly to the host by means of a vector such as a virus or nanoparticle. In cell-based gene therapies, on the other hand, genetic material is introduced to a patient’s cells ex vivo, and then the modified cells are returned to...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...